Moreover, Transwell migration assays showed that GFs treated with human recombinant TGF-β1 (10 ng/mL) strongly enhanced migration of GIST-T1 and GIST882 cells, while this effect was significantly decreased by an anti-TGF-β1 blocking antibody (Fig. 4d–g). The gene discussed is TGFB1; the disease is gastrointestinal stromal tumor.